Membranous lupus nephritis secondary to secukinumab therapy: A case report and literature review
We report the case of a 57-year-old man who developed membranous lupus nephritis after secukinumab treatment for psoriasis. Anti-SSA and PM-Scl antibodies were positive. dsDNA, anti-Smith, and anti-histone antibodies were negative, and serum complement was low. Secukinumab was discontinued, while tacrolimus was initiated, subsequently switched to cyclosporin, belimumab, glucocorticosteroid, and hydroxychloroquine with a good response. The relationship between lupus erythematosus and IL-17 inhibition requires further research.PMID:38569663 | DOI:10.1177/09612033241242698 (Source: Lupus)
Source: Lupus - April 3, 2024 Category: Rheumatology Authors: Yi Zhou Zhangxue Hu Source Type: research
Tolerability of Narrow-band Ultraviolet-B Phototherapy for Different Dermatological Diseases in Relation to Co-medications
Acta Derm Venereol. 2024 Apr 3;104:adv35215. doi: 10.2340/actadv.v104.35215.ABSTRACTPhototherapy is an efficient therapy for a variety of skin diseases. Various drugs can cause photosensitivity and impact tolerability of phototherapy. The tolerability was investigated of narrowband ultraviolet-B 311 nm therapy in dependence on the underlying disease and long-term co-medication. A total of 534 narrowband ultraviolet-B therapy courses were examined. Compared with psoriasis, adverse events were observed more frequently in eczematous diseases and, in some cases, other indications. About two-thirds of all courses were carried o...
Source: Acta Derm Venereol A... - April 3, 2024 Category: Dermatology Authors: Anna M Halupczok Ann-Sophie Bohne Sascha Gerdes Stephan Weidinger Michael Weichenthal Source Type: research
Tolerability of Narrow-band Ultraviolet-B Phototherapy for Different Dermatological Diseases in Relation to Co-medications
Acta Derm Venereol. 2024 Apr 3;104:adv35215. doi: 10.2340/actadv.v104.35215.ABSTRACTPhototherapy is an efficient therapy for a variety of skin diseases. Various drugs can cause photosensitivity and impact tolerability of phototherapy. The tolerability was investigated of narrowband ultraviolet-B 311 nm therapy in dependence on the underlying disease and long-term co-medication. A total of 534 narrowband ultraviolet-B therapy courses were examined. Compared with psoriasis, adverse events were observed more frequently in eczematous diseases and, in some cases, other indications. About two-thirds of all courses were carried o...
Source: Acta Dermato-Venereologica - April 3, 2024 Category: Dermatology Authors: Anna M Halupczok Ann-Sophie Bohne Sascha Gerdes Stephan Weidinger Michael Weichenthal Source Type: research
Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease
CONCLUSIONS: Between originator adalimumab and biosimilar-start cohorts, no differences were observed, between originator adalimumab and switch cohorts, no significant differences were found either, and with the pre- and post-switch to biosimilar comparison, 2 of the 9 patients experienced AEs after the switch. The biosimilar showed a favorable safety profile (one patient with a serious adverse effect (rash) with biosimilar discontinued treatment) and no significant changes to clinical or biochemical parameters were observed after the switch.PMID:38570210 | DOI:10.1016/j.farma.2024.01.002 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - April 3, 2024 Category: Drugs & Pharmacology Authors: Jaime E Poquet-Jornet In és Ibáñez-Sala Teresa Garrigues-Pelufo Adri án Munilla-Das Antonio Valdivia-P érez Francisco Javier Carrera-Hueso Source Type: research
A Novel Human Interleukin ‐23A Overexpressing Mouse Model of Systemic Lupus Erythematosus
ConclusionWe have generated and characterized a novel genetic mouse model of SLE, providing proof-of-concept for the etiopathogenic role of human IL-23A. This new model has a normal life span and integrates several characteristics of the human disease's complexity and chronicity, making it an attractive preclinical tool for studying IL-23 –dependent pathogenic mechanisms and assessing the efficacy of anti–human IL-23A or modeled disease-related therapeutics. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - April 3, 2024 Category: Rheumatology Authors: Eleni Christodoulou ‐Vafeiadou,
Christina Geka,
Lida Iliopoulou,
Lydia Ntari,
Maria C. Denis,
Niki Karagianni,
George Kollias Tags: Full Length Source Type: research
Unicentric Castleman ’s disease in the parotid gland associated with psoriasis: a case report
ConclusionsClinicians should be aware of the possibility of Castleman ’s disease when faced with masses or enlarged lymph nodes in the parotid gland to avoid misdiagnosis, especially in patients with autoimmune diseases and elevated serum interleukin-6. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - April 3, 2024 Category: General Medicine Source Type: research
Prevention of Psoriatic Arthritis
Psoriatic arthritis (PsA) is a systemic chronic inflammatory disease that develops in up to 30% of patients with psoriasis. Mixed data variably support the potential ability to “prevent” and/or delay PsA through use of systemic therapies in psoriasis patients. Though intriguing, almost all of these studies are retrospective in nature, and hold substantial limitations and potential biases that challenge the ability to meaningfully interpretation their results. Thus, the authors believe prospective observational and interventional studies are crucial to understanding our ability to truly modify the transition from psoria...
Source: Dermatologic Clinics - April 3, 2024 Category: Dermatology Authors: Alexander Wu, Jose U. Scher, Alexis Ogdie, Christopher Ritchlin, Joseph F. Merola Source Type: research
Oral Psoriasis Therapies
Oral psoriasis therapies include both older traditional immunosuppressants, such as methotrexate, cyclosporine, and acitretin, as well as newer, more targeted agents, such as apremilast, deucravacitinib, and oral interleukin-23 receptor antagonists. Patients may prefer oral therapies to injectable therapies based on the route of administration. Both older and newer oral psoriasis therapies can be utilized effectively in the treatment of psoriasis. Here, we will review oral agents used in the treatment of psoriasis as well as provide commentary on their role in our current, evolving psoriasis treatment paradigm. (Source: Dermatologic Clinics)
Source: Dermatologic Clinics - April 3, 2024 Category: Dermatology Authors: JaBreia James, Tracey Otto, Julia Gao, Martina L. Porter Source Type: research
Dermatologists' Perspectives on Biosimilars
Conclusion: Biosimilars are safe and effective for treating approved dermatological conditions and may lower patient costs compared to their reference products. Patients are not always offered biosimilar therapy as an option, which may be due to unfamiliarity among dermatologists. This survey suggests a need for more research and educational initiatives, such as modules and workshops that focus on biosimilar safety, efficacy, and interchangeability guidelines. J Drugs Dermatol. 2024;23(4):doi:10.36849/JDD.7755.PMID:38564397 | DOI:10.36849/JDD.7755 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Priscila Arellano Zameza Christina Kontzias Keith Flanders Peter Sonnenreich Steven R Feldman Source Type: research
Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab
J Dermatolog Treat. 2024 Dec;35(1):2334791. doi: 10.1080/09546634.2024.2334791. Epub 2024 Apr 2.ABSTRACTGeneralized pustular psoriasis (GPP) in pregnancy can lead to severe complications for both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant and severe cases. Until present, there are no evidence-based guidelines for the treatment of GPP in pregnancy. Spesolimab, a human monoclonal antibody against the IL-36 receptor, has recently attracted attention as a new therapy for GPP flare. This biologic provides rapid and sustained control of symptoms of GPP flare, although its use in pr...
Source: Journal of Dermatological Treatment - April 2, 2024 Category: Dermatology Authors: Chenxin Yang Yang Wang Ruoyu Li Ping Tu Ruojun Wang Source Type: research
Geniposide alleviates imiquimod-induced psoriasis-like skin lesions in mice via inhibition of angiogenesis
In this study, we aimed to evaluate the protective effect of geniposide (GEN) on imiquimod (IMQ)-induced psoriasis-like skin lesions in mice. Firstly, visual changes of psoriatic skin lesions were observed and the severity was recorded using psoriasis area and severity index (PASI) score. Histological changes were assessed by HE staining for epidermal thickness and Masson's staining for collagen fibers. Then, photographs of microvascular inside the skin were taken for macroscopic observation, and microscopic changes associated with angiogenesis were evaluated. Furthermore, expression of angiogenic factors were analyzed by ...
Source: International Immunopharmacology - April 2, 2024 Category: Allergy & Immunology Authors: Jiaojiao Chen Yuan Liu Nina Yin Min Zhao Xuan Sun Yanhong Zhang Zhigang Wang Source Type: research
The skin circadian clock gene F3 as a potential marker for psoriasis severity and its bidirectional relationship with IL-17 signaling in keratinocytes
CONCLUSION: Our research revealed a bidirectional link between the skin circadian gene F3 and the IL-17 signaling pathway in psoriasis, suggesting that F3 may interact with the IL-17 pathway by activating JAK-STAT within keratinocytes and inducing abnormal intracellular inflammation.PMID:38565044 | DOI:10.1016/j.intimp.2024.111993 (Source: International Immunopharmacology)
Source: International Immunopharmacology - April 2, 2024 Category: Allergy & Immunology Authors: Xiuqing Yuan Caixin Ou Xinhui Li Zhe Zhuang Yongfeng Chen Source Type: research
Interferon-Alpha Induces Psoriatic Inflammation in Mice by Phosphorylating FOXO3
J Interferon Cytokine Res. 2024 Apr 2. doi: 10.1089/jir.2023.0225. Online ahead of print.ABSTRACTPsoriasis is a chronic, immune-mediated inflammatory skin disease characterized by epidermal thickening and inflammatory cell infiltration. Excessive proliferation of keratinocytes and resistance to apoptosis lead to thickening of the epidermis. Plasmacytoid dendritic cells are involved in the occurrence of psoriasis mainly by secreting interferon-alpha (IFN-α). IFN-α is a glycoprotein with antiviral, antitumor, and immunomodulatory effects, but its role in psoriasis remains unclear. In this investigation, a mild psoriatic ph...
Source: Cell Research - April 2, 2024 Category: Cytology Authors: Hanjiang Gu Xiaoyu Wang Mei Lu Yaqi Wang Kaixuan Ren Yitian Zhang Wei Liu Guanglei Hu Weihui Zeng Yumin Xia Source Type: research
Dermatologists' Perspectives on Biosimilars
Conclusion: Biosimilars are safe and effective for treating approved dermatological conditions and may lower patient costs compared to their reference products. Patients are not always offered biosimilar therapy as an option, which may be due to unfamiliarity among dermatologists. This survey suggests a need for more research and educational initiatives, such as modules and workshops that focus on biosimilar safety, efficacy, and interchangeability guidelines. J Drugs Dermatol. 2024;23(4):doi:10.36849/JDD.7755.PMID:38564397 | DOI:10.36849/JDD.7755 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Priscila Arellano Zameza Christina Kontzias Keith Flanders Peter Sonnenreich Steven R Feldman Source Type: research
Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab
J Dermatolog Treat. 2024 Dec;35(1):2334791. doi: 10.1080/09546634.2024.2334791. Epub 2024 Apr 2.ABSTRACTGeneralized pustular psoriasis (GPP) in pregnancy can lead to severe complications for both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant and severe cases. Until present, there are no evidence-based guidelines for the treatment of GPP in pregnancy. Spesolimab, a human monoclonal antibody against the IL-36 receptor, has recently attracted attention as a new therapy for GPP flare. This biologic provides rapid and sustained control of symptoms of GPP flare, although its use in pr...
Source: Journal of Dermatological Treatment - April 2, 2024 Category: Dermatology Authors: Chenxin Yang Yang Wang Ruoyu Li Ping Tu Ruojun Wang Source Type: research
